# US 2023/0404107 A1 · Berberine alkaloids in the prevention and/or treatment of intestinal disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0404107 A1
- Document ID: US20230404107A1
- Status: Published application
- Kind: A1
- Application number: 16/499,155
- Filed: 2018-01-02
- Published: 2023-12-21
- Earliest claimed: 2017-03-28
- Assignees: IRP Health Pty Ltd
- Applicants: IRP Health Pty Ltd
- Inventors: David Xiang YU; Zhicheng XIAO; Colin William POUTON; Zhiyong HE
- Web page: https://patentgrep.com/patent/US20230404107A1

## CPC

- A23K 20/132: containing only one nitrogen as hetero atom
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A23K 10/00: Animal feeding-stuffs
- A23K 20/10: Organic substances
- A23K 20/121: containing oxygen or sulfur as hetero atom
- A23K 50/30: for swines
- A23K 50/75: for poultry
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61P 31/04: Antibacterial agents
- A61P 33/00: Antiparasitic agents
- A23K: FODDER
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention relates to berberine alkaloids, formulations thereof and their use for the prevention and/or treatment of infectious disease, especially disease caused by C. perfringens and Eimeria in animals. The invention also relates to improving the feed conversion ratio in a food producing animal by administering berberine compositions.

## Claims

### Claim 1

A method for the prevention and/or treatment of an infectious disease in a chicken, wherein the method comprises administering a berberine alkaloid thereof to the chicken, wherein the infectious disease is caused by bacteria from the genus Clostridium.

### Claim at position 2

-12. (canceled)

### Claim 13 (depends on 1)

The method according to claim 1, wherein the infectious disease is caused by antibiotic-resistant bacteria from the genus Clostridium.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the infectious disease is Necrotic enteritis.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the Necrotic enteritis is caused by a C. perfringens type A strain, C. perfringens type A strain EHE-NE36, C. perfringens type A strain EHE-NE18, or a C. perfringens type C strain.

### Claim at position 6

-19. (canceled)

### Claim 20 (depends on 1)

The method according to claim 1, wherein the administration occurs via the feed or water of the chicken.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the feed is the form of a crumble or a pellet.

### Claim 22 (depends on 1)

The method according to claim 1, wherein the berberine alkaloid is administered at a dose of 0.001 g/kg to 2 g/kg of feed or; at a dose of 0.001 g/L to 0.1 g/L of water.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

The method according to claim 1, wherein (i) lesion score is decreased and/or the fecal oocyst count in the chicken is reduced; (ii) there is a reduction in morbidity; or (iii) there is a reduction in mortality.

### Claim at position 12

-26. (canceled)

### Claim 27 (depends on 14)

The method according to claim 14, wherein: (i) there is a safe residue level of the berberine alkaloid in the muscle tissue of the chicken after the prevention and/or treatment period; (ii) there is a safe residue level of the berberine alkaloid in the muscle tissue of the chicken after the treatment period and a washout period; (iii) there is a safe residue level of the berberine alkaloid in the liver and muscle tissue of the chicken after the treatment period; or (iv) there is a safe residue level of the berberine alkaloid in the liver and muscle tissue of the chicken after the treatment period and a washout period; or (v) there is a safe residue level of the berberine alkaloid in the liver tissue of the chicken after the treatment period and a washout period.

### Claim at position 14

-69. (canceled)

### Claim 70 (depends on 1)

The method according to claim 1, wherein the berberine alkaloid is berberine hemisulfate.

### Claim 71 (depends on 1)

The method according to claim 1, wherein the berberine alkaloid is berberine chloride.

### Claim 72 (depends on 1)

The method according to claim 1, further comprising an additive that masks a bitter flavour of the berberine alkaloid.

### Claim at position 18

-91. (canceled)

### Claim 92 (depends on 2)

The method according to claim 2, wherein the antibiotic-resistant bacteria are C. perfringens.
